Improving Congenital Heart Disease Care
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Aug 26, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Improving Congenital Heart Disease Care" is studying a new digital tool called "Empower My Congenital Health" (EmpowerMyCH). This tool is designed to help adults with congenital heart disease feel more confident and engaged in managing their health as they transition to adult healthcare. It includes features like a digital medical passport, updated health information, community support, and personal stories from other patients. The goal is to see how well this tool works in helping patients navigate their healthcare and improve their quality of life.
To participate in this trial, individuals must be 18 years or older and have congenital heart disease. They should also be able to sign a consent form to join. Unfortunately, those who have developmental delays and cannot provide consent are not eligible. Participants will be able to use the EmpowerMyCH tool and help researchers understand its effectiveness. This trial is currently recruiting, and anyone interested in learning more is encouraged to reach out.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • have congenital heart disease
- • 18 years or older
- • can sign the informed consent
- Exclusion Criteria:
- • developmentally delayed
- • unable to consent
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Anushree Agarwal, MBBS, MAS
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported